Date: 2013-12-05
Type of information:
phase:
Announcement: results
Company: Marinomed Biotechnologie (Austria)
Product: Carragelose®-based nasal spray
Action mechanism: Marinomed\'s antiviral nasal spray using Carragelose® creates a protective layer preventing viruses from entering the nasal mucosa and is the first product effective against a broad spectrum of respiratory viruses worldwide. The nasal spray is currently marketed in Austria and 15 other countries worldwide.
Disease: common cold
Therapeutic area: Infectious diseases
Country:
Trial details: In a randomized, double-blind placebo-controlled trial 211 patients suffering from early symptoms of the common cold were treated. Each patient received either an antiviral nasal spray or placebo three times per day and the progress of the disease was observed for 21 days.
Latest
news: * On December 5, 2013, Marinomed Biotechnologie has announced that new clinical data confirmed the effectiveness of a Carragelose®-based nasal spray in the therapy of common cold. The data, generated in collaboration with researchers from the Department of Otolaryngology at the Medical University of Vienna, were published in Respiratory Research. Regular use of the product, which for the first time addresses the causes of common cold through its antiviral activity, significantly reduces the duration of common cold symptoms and leads to a significant decrease in the viral load in the nasal wash of patients. In a randomized, double-blind placebo-controlled trial 211 patients suffering from early symptoms of the common cold were treated. Each patient received either an antiviral nasal spray or placebo three times per day and the progress of the disease was observed for 21 days. In virus-infected patients, who had received the Carragelose® nasal spray, alleviation of symptoms was significantly faster compared to the control group. The difference between the groups amounted to 2.1 days on average. This positive result is supported by significantly faster clearing of viruses in the Carragelose® nasal spray group. The paper is entitled \"Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial\" by Martin Ludwig, Elisabeth Enzenhofer, Sven Schneider, Margit Rauch, Angelika Bodenteich, Kurt Neumann, Eva Prieschl-Grassauer, Andreas Grassauer, Thomas Lion und Christian A. Mueller has been published on November 13th 2013 in Respiratory Research, Volume 14:124.
